Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

432 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Implementing proximity care for people with multiple sclerosis in Italy: the bottom-up approach of the StayHome project.
Filippi M, Gallo P, Gasperini C, Marfia GA, Avolio C, Bergamaschi R, Capobianco M, Dotta M, Grimaldi L, Lus G, Patti F, Pucci E, Quatrale R, Solla P, Bandiera P, Angioletti C, Gallottini MC, Parretti S, Pinto L, Pavone F, Sanzone S; StayHome Project Working Group. Filippi M, et al. Among authors: grimaldi l. J Neurol. 2025 Jan 7;272(1):96. doi: 10.1007/s00415-024-12749-8. J Neurol. 2025. PMID: 39775071 Free PMC article.
No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.
Landi D, De Rossi N, Zagaglia S, Scarpazza C, Prosperini L, Albanese M, Buttari F, Mori F, Marfia GA, Sormani MP, Capra R, Centonze D; Italian PML study group. Landi D, et al. Neurology. 2017 Mar 21;88(12):1144-1152. doi: 10.1212/WNL.0000000000003740. Epub 2017 Feb 22. Neurology. 2017. PMID: 28228569 Free article.
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.
Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulović J, Giovannoni G, Hartung HP, Arnold DL, Fisher E, Rudick R, Mi S, Chai Y, Li J, Zhang Y, Cheng W, Xu L, Zhu B, Green SM, Chang I, Deykin A, Sheikh SI; SYNERGY study investigators. Cadavid D, et al. Lancet Neurol. 2019 Sep;18(9):845-856. doi: 10.1016/S1474-4422(19)30137-1. Epub 2019 Jul 5. Lancet Neurol. 2019. PMID: 31285147 Clinical Trial.
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators. Kapoor R, et al. Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12. Lancet Neurol. 2018. PMID: 29545067 Clinical Trial.
Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).
Butzkueven H, Kappos L, Wiendl H, Trojano M, Spelman T, Chang I, Kasliwal R, Jaitly S, Campbell N, Ho PR, Licata S; Tysabri Observational Program (TOP) Investigators. Butzkueven H, et al. J Neurol Neurosurg Psychiatry. 2020 Jun;91(6):660-668. doi: 10.1136/jnnp-2019-322326. Epub 2020 Mar 31. J Neurol Neurosurg Psychiatry. 2020. PMID: 32234967 Free PMC article.
Lack of association between IL-1A and IL-1B promoter polymorphisms and multiple sclerosis.
Ferri C, Sciacca FL, Grimaldi LE, Veglia F, Magnani G, Santuccio G, Comi G, Canal N, Grimaldi LM. Ferri C, et al. Among authors: grimaldi lm, grimaldi le. J Neurol Neurosurg Psychiatry. 2000 Oct;69(4):564-5. doi: 10.1136/jnnp.69.4.564. J Neurol Neurosurg Psychiatry. 2000. PMID: 11183041 Free PMC article. No abstract available.
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Hauser SL, et al. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002679 Free article. Clinical Trial.
Shaping the future of pharmacoepidemiology in France: Recommendations from the SFPT Pharmacoepidemiology Working Group.
Soeiro T, Allouchery M, Bene J, Bezin J, Dolladille C, Faillie JL, Grimaldi L, Kaguelidou F, Khouri C, Lafaurie M, Largeau B, Montastruc F, Morin L, Scailteux LM, Pariente A; SFPT Pharmacoepidemiology Working Group. Soeiro T, et al. Among authors: grimaldi l. Therapie. 2024 Dec 14:S0040-5957(24)00213-0. doi: 10.1016/j.therap.2024.12.005. Online ahead of print. Therapie. 2024. PMID: 39706774 Free article. Review.
Neuropsychological tests at the Italian Centers for Cognitive Disorders and Dementias: results from a survey on 450 specialized services.
Vaccaro R, Lorenzini P, Giaquinto F, Matascioli F, Carnevale G, Sciancalepore F, Gasparini M, Salvi E, Corbo M, Locuratolo N, Vanacore N, Bacigalupo I; Permanent Table of the National Dementia Plan Study Group; CCDDs Study Group. Vaccaro R, et al. Aging Clin Exp Res. 2024 Dec 20;37(1):1. doi: 10.1007/s40520-024-02869-6. Aging Clin Exp Res. 2024. PMID: 39704981 Free PMC article.
ApoE: The Non-Protagonist Actor in Neurological Diseases.
Grimaldi L, Bovi E, Formisano R, Sancesario G. Grimaldi L, et al. Genes (Basel). 2024 Oct 30;15(11):1397. doi: 10.3390/genes15111397. Genes (Basel). 2024. PMID: 39596597 Free PMC article. Review.
432 results